Fifth Third Bancorp
CRSP icon

Fifth Third Bancorp’s CRISPR Therapeutics CRSP Stock Holding History

Fifth Third Bancorp’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.83K Buy
+33
New +$1.78K ﹤0.01% 4099
2025
Q3 		– Sell
-15
Closed -$730 – 2689
2025
Q2 		$730 Sell
15
-5
-25% -$193 ﹤0.01% 2462
2025
Q1 		$681 Buy
+20
New +$848 ﹤0.01% 2428
2024
Q4 		– Sell
-250
Closed -$11.7K – 2533
2024
Q3 		$11.7K Hold
250
– – ﹤0.01% 1942
2024
Q2 		$13.5K Hold
250
– – ﹤0.01% 1839
2024
Q1 		$17K Sell
250
-125
-33% -$8.95K ﹤0.01% 1699
2023
Q4 		$23.5K Hold
375
– – ﹤0.01% 1721
2023
Q3 		$17K Sell
375
-350
-48% -$18.1K ﹤0.01% 1795
2023
Q2 		$40.7K Hold
725
– – ﹤0.01% 1450
2023
Q1 		$32.8K Hold
725
– – ﹤0.01% 1619
2022
Q4 		$29.5K Hold
725
– – ﹤0.01% 1560
2022
Q3 		$47K Hold
725
– – ﹤0.01% 1335
2022
Q2 		$44K Buy
725
+125
+21% +$7.35K ﹤0.01% 1409
2022
Q1 		$38K Sell
600
-1,050
-64% -$65.9K ﹤0.01% 1560
2021
Q4 		$125K Buy
1,650
+500
+43% +$43.7K ﹤0.01% 1164
2021
Q3 		$129K Buy
1,150
+450
+64% +$56.5K ﹤0.01% 1103
2021
Q2 		$113K Hold
700
– – ﹤0.01% 1151
2021
Q1 		$85K Hold
700
– – ﹤0.01% 1205
2020
Q4 		$107K Hold
700
– – ﹤0.01% 1132
2020
Q3 		$59K Hold
700
– – ﹤0.01% 1276
2020
Q2 		$51K Buy
700
+250
+56% +$14.6K ﹤0.01% 1299
2020
Q1 		$19K Buy
450
+350
+350% +$18.1K ﹤0.01% 1539
2019
Q4 		$6K Hold
100
– – ﹤0.01% 1925
2019
Q3 		$4K Hold
100
– – ﹤0.01% 1951
2019
Q2 		$5K Hold
100
– – ﹤0.01% 1989
2019
Q1 		$4K Hold
100
– – ﹤0.01% 1960
2018
Q4 		$3K Hold
100
– – ﹤0.01% 2047
2018
Q3 		$4K Buy
100
+20
+25% +$1.05K ﹤0.01% 2011
2018
Q2 		$5K Buy
+80
New +$4.56K ﹤0.01% 2037

Other funds holding CRSP

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Fifth Third Bancorp's CRSP Position: Q3 2026 in Review

Fifth Third Bancorp opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 33 shares worth $1.83K. The stake represents ﹤0.01% of the portfolio and ranks #4099 among its holdings. This is a return to the name: Fifth Third Bancorp previously reported a position in CRSP as recently as Q2 2025.

Fifth Third Bancorp first reported a position in CRSP in Q2 2018 and has held it in 29 quarters since. The position peaked at $129K in Q3 2021. 286 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Fifth Third Bancorp held 33 shares of CRISPR Therapeutics worth $1.83K as of Q3 2026.
  • CRISPR Therapeutics was a new Fifth Third Bancorp position in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q3 2026, its #4099 holding.
  • Fifth Third Bancorp first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Fifth Third Bancorp's CRISPR Therapeutics position peaked at $129K in Q3 2021.
  • 286 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Fifth Third Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.